Literature DB >> 21456071

Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer.

Jacek Pinski1, Shigang Xiong, Qingcai Wang, Frank Stanczyk, Debra Hawes, Stephen V Liu.   

Abstract

BACKGROUND: Recent data has shown that prostate cancer (PCA) cells are capable of producing testosterone directly from cholesterol, which may contribute to the development of castration resistance. While up-regulation of steroidogenic enzymes has been previously described during castration-resistant prostate cancer (CRPC) progression, regulation of this process is poorly defined. These data examine the role of luteinizing hormone (LH) in the regulation of steroidogenic machinery in PCA cells.
METHODS: PCA cell lines LNCaP, C4-2B, and 22RV1 were exposed to LH. Gene expression was quantified using real-time PCR and protein expression was characterized with standard Western blot analysis. Steroid analysis was performed using radioimmunoassay (RIA). Cell viability was measured using an MTS viability assay.
RESULTS: Androgen-sensitive (LNCaP) and -independent PCA cells (C4-2B and 22RV1) express both mRNA and protein for LH and LH receptor (LHR). Exposure of these cells to LH for 4 hr increased the expression of several steroidogenic genes. Exposure for 10 days resulted in the increase of additional genes. At both time points, the upregulation of these genes was dose-dependent. This was mirrored by an increase in the expression of several key steroidogenic enzymes, including StAR, CYB5B, CYP11A, and 3βHSD. LH stimulated the production of progesterone and testosterone in LNCaP cells as measured by RIA. We have also demonstrated that treatment of LNCaP cells with LH enhanced their viability.
CONCLUSIONS: Our data show that LH-mediated activation of LHR significantly up-regulates the expression of genes and enzymes required for steroidogenesis and increases steroid production in PCA cells.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21456071     DOI: 10.1002/pros.21305

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  10 in total

1.  The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy.

Authors:  Luis A Kluth; Shahrokh F Shariat; Christian Kratzik; Scott Tagawa; Guru Sonpavde; Malte Rieken; Douglas S Scherr; Karl Pummer
Journal:  World J Urol       Date:  2013-09-03       Impact factor: 4.226

2.  "Been hit twice": a novel bi-allelic heterozygous mutation in LHCGR.

Authors:  T Rajendra Kumar
Journal:  J Assist Reprod Genet       Date:  2014-07       Impact factor: 3.412

3.  Amidoxime reductase system containing cytochrome b5 type B (CYB5B) and MOSC2 is of importance for lipid synthesis in adipocyte mitochondria.

Authors:  Etienne P A Neve; Asa Nordling; Tommy B Andersson; Ulf Hellman; Ulf Diczfalusy; Inger Johansson; Magnus Ingelman-Sundberg
Journal:  J Biol Chem       Date:  2011-12-27       Impact factor: 5.157

4.  Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.

Authors:  Peter B Østergren; Caroline Kistorp; Mikkel Fode; James Henderson; Finn N Bennedbæk; Jens Faber; Jens Sønksen
Journal:  J Urol       Date:  2016-12-09       Impact factor: 7.450

5.  Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy.

Authors:  Christoph A von Klot; Markus A Kuczyk; Alena Boeker; Christoph Reuter; Florian Imkamp; Thomas R W Herrmann; Hossein Tezval; Mario W Kramer; Sven Perner; Axel S Merseburger
Journal:  Oncol Lett       Date:  2016-11-17       Impact factor: 2.967

6.  Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer.

Authors:  Hisamitsu Ide; Yan Lu; Takahiro Noguchi; Satoru Muto; Hiroshi Okada; Suguru Kawato; Shigeo Horie
Journal:  Cancer Sci       Date:  2018-02-19       Impact factor: 6.716

7.  Luteinizing Hormone Levels Relate to the Unfavorable Pathology of Prostate Cancer.

Authors:  Se Young Choi; Byung Hoon Chi; Wonchul Lee; Bumjin Lim; Dalsan You; Choung-Soo Kim
Journal:  J Clin Med       Date:  2020-04-29       Impact factor: 4.241

Review 8.  The use of luteinizing hormone-releasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer.

Authors:  Tomasz Milecki; Andrzej Antczak; Zbigniew Kwias; Piotr Milecki
Journal:  Contemp Oncol (Pozn)       Date:  2014-06-03

9.  Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial.

Authors:  Carsten-Henning Ohlmann; Michelle Jäschke; Peter Jaehnig; Susane Krege; Jürgen Gschwend; Heidrun Rexer; Michael Stöckle
Journal:  Trials       Date:  2017-10-04       Impact factor: 2.279

10.  Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting.

Authors:  Seung Il Jung; Myung Soo Kim; Chang Wook Jeong; Cheol Kwak; Sung Kyu Hong; Seok Ho Kang; Jae Young Joung; Seung Hwan Lee; Seok Joong Yun; Tae-Hwan Kim; Sung Woo Park; Seong Soo Jeon; Minyong Kang; Ji Youl Lee; Byung Ha Chung; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim; Dong Deuk Kwon
Journal:  Investig Clin Urol       Date:  2019-12-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.